Taurocholic acid - Satiogen Pharmaceuticals

Drug Profile

Taurocholic acid - Satiogen Pharmaceuticals

Alternative Names: sodium taurocholate - Satiogen Pharmaceuticals; taurocholate - Satiogen Pharmaceuticals

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Satiogen Pharmaceuticals
  • Class Antihyperglycaemics; Bile acids and salts; Cholic acids; Obesity therapies; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Obesity; Type 2 diabetes mellitus

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 18 Oct 2018 Discontinued - Phase-I/II for Obesity in United Arab Emirates (Rectal)
  • 18 Oct 2018 Discontinued - Phase-I/II for Type-2 diabetes mellitus in United Arab Emirates (Rectal)
  • 18 Oct 2018 Discontinued - Phase-II for Obesity in Australia (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top